[REVISION HISTORY]

Genmab clinical trial developments

1 recorded revision of this situation.

What changed

2026-10-28 19:23 UTC → 2026-10-29 20:50 UTC · added ~~removed~~

Genmab A/S has reported positive clinical trial results for multiple investigational treatments. Initial reports highlighted Phase 1/2 data for the antibody-drug conjugate rinatabart sesutecan (Rina-S) in treating platinum-resistant ovarian cancer. The RAINFOL-01 trial showed a confirmed objective response rate of 45.9% and a median progression-free survival of 9.5 months. Subsequent developments included successful Phase 3 results for the bispecific antibody petosemtamab in the LiGeR-HN1 trial. When combined with pembrolizumab, petosemtamab met primary endpoints for first-line recurrent or metastatic PD-L1-positive head and neck squamous cell carcinoma, reducing the risk of death by 50% compared to pembrolizumab alone. ~~These successes, alongside further Rina-S~~ An interim analysis of the LiGeR-HN1 trial reported an odds ratio of 3.17 for objective response, with results remaining consistent regardless of HPV status. Genmab stated the safety profile was well tolerated with no new safety signals observed. Further clinical successes include data from the ~~RAINFOL-02~~ Rina-S trial ~~and~~ for platinum-resistant ovarian cancer, which showed a 57% reduction in the risk of death. These developments, alongside petosemtamab results in metastatic colorectal cancer, have contributed to ~~a 16% surge~~ significant increases in Genmab shares. The company plans to engage with global regulatory authorities regarding these findings.

Versions

Select a version to see what changed compared to the one before it.